RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia
暂无分享,去创建一个
D. Birnbaum | P. Gestraud | E. Pasmant | J. Tamburini | S. Mouche | C. Récher | P. Tsantoulis | M. Lelorc'h | N. Vey | M. Fontenay | I. Radford‐Weiss | O. Hermine | D. Bouscary | E. Del Nery | R. Castellano | Y. Collette | O. Kosmider | J. Sarry | C. Bosc | Mathilde Gotanègre | C. Montersino | G. Fouquet | A. Guille | F. Simonetta | Anne-Sophie Alary | J. Decroocq | R. Birsen | Prasad Chaskar | Jordi Mano | L. Poulain | C. Friedrich | Hélène Guermouche | Ambrine Sahal | Auriane Lescure | Adrien Grenier | F. Mazed | J. Mondesir | N. Chapuis | Liza Ho | A. Boughalem | C. Gobeaux | É. Pasmant | M. Lelorc’h | P. Chaskar | Fetta Mazed | Laury Poulain | A. Alary | Sarah Mouche
[1] H. Dombret,et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. , 2021, Blood.
[2] Hossein Khiabanian,et al. A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. , 2021, Blood.
[3] R. Stam,et al. High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia , 2021, Translational oncology.
[4] J. Desai,et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. , 2020, The New England journal of medicine.
[5] D. Herranz,et al. A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia , 2020, bioRxiv.
[6] D. Birnbaum,et al. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study , 2020, Blood Cancer Journal.
[7] Xiufeng Pang,et al. Blocking STAT3 by Pyrvinium Pamoate Causes Metabolic Lethality in KRAS-mutant lung cancer. , 2020, Biochemical pharmacology.
[8] Quincy A. Hathaway,et al. Pyrvinium Pamoate Use in a B cell Acute Lymphoblastic Leukemia Model of the Bone Tumor Microenvironment , 2020, Pharmaceutical Research.
[9] G. Gómez-López,et al. MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia , 2019, Scientific Reports.
[10] S. Asthana,et al. Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. , 2019, Cancer discovery.
[11] J. Tamburini,et al. Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study , 2019, British journal of haematology.
[12] R. Larson,et al. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). , 2019, Blood advances.
[13] H. Kantarjian,et al. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS‐mutant Acute Myeloid Leukemia , 2019, Clinical lymphoma, myeloma & leukemia.
[14] G. Sauvageau,et al. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. , 2019, Blood advances.
[15] B. Viollet,et al. Knockdown of Human AMPK Using the CRISPR/Cas9 Genome-Editing System. , 2019, Methods in molecular biology.
[16] Chien-Yuan Chen,et al. Pyrvinium Pamoate Overcomes Cabozantinib-Resistance of FLT3-ITD AML Cells through Modulating the Mitochondria Functions and Signaling Pathways , 2018, Blood.
[17] E. Atallah,et al. Incorporating newer agents in the treatment of acute myeloid leukemia. , 2018, Leukemia research.
[18] Beth Wilmot,et al. Functional Genomic Landscape of Acute Myeloid Leukemia , 2018, Nature.
[19] H. Dombret,et al. Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. , 2018, Blood.
[20] C. Bloomfield,et al. NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome , 2018, Leukemia.
[21] Gregory P. Way,et al. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas , 2018, Cell reports.
[22] Amirhossein Sahebkar,et al. The novel role of pyrvinium in cancer therapy , 2018, Journal of cellular physiology.
[23] Markus G. Manz,et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.
[24] G. Hampton,et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types , 2018, npj Precision Oncology.
[25] J. Tamburini,et al. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia , 2018, Leukemia.
[26] Jesse D. Gelles,et al. Dual suppression of inner and outer mitochondrial membrane functions augments apoptotic responses to oncogenic MAPK inhibition , 2018, Cell Death & Disease.
[27] R. Premont,et al. Niclosamide: Beyond an antihelminthic drug , 2017, Cellular Signalling.
[28] A. Hauschild,et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.
[29] M. Carroll,et al. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. , 2017, Cancer discovery.
[30] Frank McCormick,et al. RAS Proteins and Their Regulators in Human Disease , 2017, Cell.
[31] M. L. Le Beau,et al. Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model. , 2017, Blood.
[32] M. Landthaler,et al. An immediate–late gene expression module decodes ERK signal duration , 2017, Molecular systems biology.
[33] A. Ferrando,et al. Synergistic antileukemic therapies in NOTCH1-induced T-ALL , 2017, Proceedings of the National Academy of Sciences of the United States of America.
[34] Eric S. Lander,et al. Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras , 2017, Cell.
[35] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[36] John G Doench,et al. A Genome-wide CRISPR Death Screen Identifies Genes Essential for Oxidative Phosphorylation. , 2016, Cell metabolism.
[37] Roland Eils,et al. Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..
[38] K. Shokat,et al. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design , 2016, Nature Reviews Drug Discovery.
[39] H. Kantarjian,et al. Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies , 2016, Cancer.
[40] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[41] Changfu Wang,et al. Pyrvinium selectively induces apoptosis of lymphoma cells through impairing mitochondrial functions and JAK2/STAT5. , 2016, Biochemical and biophysical research communications.
[42] Huafeng Xie,et al. Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer. , 2016, Cancer cell.
[43] S. Whittaker,et al. How I treat mycosis fungoides and Sézary syndrome. , 2016, Blood.
[44] A. Baruchel,et al. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network , 2015, Nature Genetics.
[45] S. Cook,et al. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road , 2015, Nature Reviews Cancer.
[46] C. Chuah,et al. Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration , 2015, Oncotarget.
[47] T. Golub,et al. The Genomic Landscape of Juvenile Myelomonocytic Leukemia , 2015, Nature Genetics.
[48] B. Viollet,et al. Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia. , 2015, Cell reports.
[49] N. Gray,et al. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. , 2015, Blood.
[50] N. Ratner,et al. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor , 2015, Nature Reviews Cancer.
[51] E. Pasmant,et al. Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations? , 2014, European Journal of Human Genetics.
[52] S. Lowe,et al. Preclinical efficacy of MEK inhibition in Nras-mutant AML. , 2014, Blood.
[53] S. Fesik,et al. Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.
[54] Eric Legius,et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies , 2014, Nature.
[55] G. Shulman,et al. Niclosamide ethanolamine improves blood glycemic control and reduces hepatic steatosis in mice , 2014, Nature Network Boston.
[56] Krister Wennerberg,et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies , 2014, Scientific Reports.
[57] Neville E. Sanjana,et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.
[58] Scott E. Smith,et al. Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial , 2013, Clinical Cancer Research.
[59] D. Felsher,et al. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. , 2013, Blood.
[60] Jun S. Song,et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. , 2013, Cancer cell.
[61] Y. Harada,et al. Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration , 2012, Front. Oncol..
[62] Y. Harada,et al. Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. , 2012, Cancer letters.
[63] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[64] Bruce J. Melancon,et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. , 2010, Nature chemical biology.
[65] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[66] J. Tamburini,et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. , 2009, Blood.
[67] P. Yaswen,et al. A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells , 2009, PloS one.
[68] Sungjoon Kim,et al. Ba/F3 cells and their use in kinase drug discovery , 2007, Current opinion in oncology.
[69] T. Haferlach,et al. Implications of NRAS mutations in AML: a study of 2502 patients. , 2006, Blood.
[70] R. Berger,et al. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique , 2006, Leukemia.
[71] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[72] R. Hills,et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. , 2005, Blood.
[73] G. Laurent,et al. Antileukemic activity of rapamycin in acute myeloid leukemia. , 2005, Blood.
[74] R. Verhaak,et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.
[75] F. Verdier,et al. Erythropoietin‐induced erythroid differentiation of the human erythroleukemia cell line TF‐1 correlates with impaired STAT5 activation. , 1996, The EMBO journal.
[76] C. Schölzel,et al. Stimulation of proliferation and differentiation of acute myeloid leukemia cells on a bone marrow stroma in culture. , 1985, Experimental hematology.